JP2022519249A - 結晶性二酸化ケイ素の封鎖 - Google Patents
結晶性二酸化ケイ素の封鎖 Download PDFInfo
- Publication number
- JP2022519249A JP2022519249A JP2021544602A JP2021544602A JP2022519249A JP 2022519249 A JP2022519249 A JP 2022519249A JP 2021544602 A JP2021544602 A JP 2021544602A JP 2021544602 A JP2021544602 A JP 2021544602A JP 2022519249 A JP2022519249 A JP 2022519249A
- Authority
- JP
- Japan
- Prior art keywords
- silicon dioxide
- crystalline silicon
- quartz
- range
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910021488 crystalline silicon dioxide Inorganic materials 0.000 title claims abstract description 37
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 15
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000005995 Aluminium silicate Substances 0.000 claims abstract description 14
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000012211 aluminium silicate Nutrition 0.000 claims abstract description 14
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 9
- 238000000227 grinding Methods 0.000 claims abstract description 8
- 229910052710 silicon Inorganic materials 0.000 claims abstract 2
- 239000010703 silicon Substances 0.000 claims abstract 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 110
- 235000012239 silicon dioxide Nutrition 0.000 claims description 64
- 239000010453 quartz Substances 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 25
- 239000002245 particle Substances 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 18
- 239000000377 silicon dioxide Substances 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 230000000770 proinflammatory effect Effects 0.000 claims description 12
- 231100000433 cytotoxic Toxicity 0.000 claims description 9
- 230000001472 cytotoxic effect Effects 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 229940127557 pharmaceutical product Drugs 0.000 claims description 5
- 229910052906 cristobalite Inorganic materials 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 description 25
- 101150031350 Cxcl2 gene Proteins 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 20
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 239000013642 negative control Substances 0.000 description 15
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 14
- 210000001132 alveolar macrophage Anatomy 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 11
- 231100000135 cytotoxicity Toxicity 0.000 description 10
- 230000003013 cytotoxicity Effects 0.000 description 10
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 201000010001 Silicosis Diseases 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 229910004298 SiO 2 Inorganic materials 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 210000003622 mature neutrocyte Anatomy 0.000 description 4
- 239000012925 reference material Substances 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000002247 constant time method Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 3
- 229920000151 polyglycol Polymers 0.000 description 3
- 239000010695 polyglycol Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 101150003028 Hprt1 gene Proteins 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- -1 PEG500 Polymers 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229920002717 polyvinylpyridine Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000010421 standard material Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 229910021489 α-quartz Inorganic materials 0.000 description 2
- WKBPZYKAUNRMKP-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)pentyl]1,2,4-triazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(CCC)CN1C=NC=N1 WKBPZYKAUNRMKP-UHFFFAOYSA-N 0.000 description 1
- GXDMUOPCQNLBCZ-UHFFFAOYSA-N 3-(3-triethoxysilylpropyl)oxolane-2,5-dione Chemical compound CCO[Si](OCC)(OCC)CCCC1CC(=O)OC1=O GXDMUOPCQNLBCZ-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000011050 LAL assay Methods 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 1
- 101000894527 Momordica charantia Glu S.griseus protease inhibitor Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 238000003991 Rietveld refinement Methods 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910021486 amorphous silicon dioxide Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000010499 anthracosilicosis Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002817 coal dust Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910002026 crystalline silica Inorganic materials 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 231100000003 human carcinogen Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052622 kaolinite Inorganic materials 0.000 description 1
- 238000007561 laser diffraction method Methods 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000616 occupational exposure limit Toxicity 0.000 description 1
- 229920000364 para-Aramid fibril Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000721 toxic potential Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229910021654 trace metal Inorganic materials 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000004876 x-ray fluorescence Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B33/00—Silicon; Compounds thereof
- C01B33/113—Silicon oxides; Hydrates thereof
- C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
- C01B33/18—Preparation of finely divided silica neither in sol nor in gel form; After-treatment thereof
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
- A62D3/00—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances
- A62D3/30—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances by reacting with chemical agents
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
- A62D2101/00—Harmful chemical substances made harmless, or less harmful, by effecting chemical change
- A62D2101/40—Inorganic substances
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/51—Particles with a specific particle size distribution
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/62—Submicrometer sized, i.e. from 0.1-1 micrometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/80—Compositional purity
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Business, Economics & Management (AREA)
- Emergency Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Silicon Compounds (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Disintegrating Or Milling (AREA)
- Medicinal Preparation (AREA)
- Glass Compositions (AREA)
- Pigments, Carbon Blacks, Or Wood Stains (AREA)
- Detergent Compositions (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
陰性対照(試料:1):D-MEM細胞培養培地+10% FCS
非粒子陰性/ビヒクル対照として、Dulbecco's Minimum Essential Medium(D-MEM)を、文献(Ziemann et al, 2017, and Ziemann C, Reamon-Buettner SM, Tillmann T et al. (2014b) The SILICOAT project: In vitro and in vivo toxicity screening of quartz varieties from traditional ceramics industry and approaches for an effective quartz surface coating. Naunyn Schmiedebergs Arch Pharmacol; 387 (Suppl 1): p. 23)に従って、高グルコース(4.5g/l)、Life Technologies GmbH(ダルムシュタット、ドイツ)のGlutaMaxTM及びピルビン酸ナトリウム(110mg/l)と共に使用した。
石英で誘導される効果からの全般的な微粒子効果(general particulate effects)を区切ることができるようにするために、酸化アルミニウム(Al2O3;「酸化アルミニウム粉末、<10mm、不純物金属に基づく純度(trace metal basis)99.5%」;Sigma-Aldrich Chemie GmbH、ミュンヘン)を粒子状陰性対照として一緒に用いた。in vitro研究では、モデル系において、Al2O3には有害な生物学的活性がほとんどないことが示されていた(Ziemann et al., 2009; Ziemann et al., 2014; Ziemann et al., 2017)。
石英による効果の陽性対照として、ヨーロッパにおける実験毒性学のための容認された陽性標準(Robock (1973), Standard quartz DQ12 < 5 μm for experimental pneumoconiosis research projects in the Federal Republic of Germany. Ann Occup Hyg; 16: 63-6; Clouter et al. (2001) Inflammatory effects of respirable quartz collected in workplaces versus standard DQ12 quartz: particle surface correlates. Toxicol Sci; 63: 90-8; Creutzenberg et al. (2008) Toxicity of a quartz with occluded surfaces in a 90-day intratracheal instillation study in rats. Inhal Toxicol; 20: 995-1008)を表す、デレントルプ(D[oe]rentrup)であるQuartz DQ12(α-石英87%、非晶質SiO213%;質量平均幾何学的径:2.99±1.53μm;ベルグバウフォルシュン、エッセン、ドイツ)を使用した。DQ12は使用されたモデル系(Monfort et al., 2008; Ziemann et al., 2009, 2014 and 2017)においてDNAと膜損傷を再現性よく誘導し、ラットの肺に炎症反応を引き起こすことができる。
石英による生物学的効果を、石英によって媒介されない効果と区別することができるように、各石英粉試料を乳酸アルミニウム(アルミニウム100μM;Sigma-Aldrich Chemie GmbH、ミュンヘン)の有無下で試験した。石英による生物学的影響に対するALの不活性化作用は、ラット由来の一次肺胞マクロファージ(AM)で繰り返し確認できた(Monfort et al., 2008; Ziemann et al., 2009; Ziemann et al., 2014; Ziemann et al., 2017)。
乳酸デヒドロゲナーゼ(LDH)放出に関する実験のために、陽性対照(高対照(high control))及び計算基準(100%細胞毒性)としてTriton X-100で細胞を処理した。この非イオン性界面活性剤で細胞を処理することによって、細胞膜は完全に損傷を受け、存在する通常細胞内に局在する乳酸デヒドロゲナーゼ(LDH)酵素がすべて放出される。
まず、二酸化結晶シリコンについては、それに対応する汚染がin vitro検査で非特異的効果をもたらす可能性があることから、無菌性及び内毒含有量について検討した。特に、炎症誘発性を試験するためのエンドポイントは、アーチファクトの影響を受ける可能性がある。
AMの前培養物をZiemann et al., 2017に従って調製し、試験材料及び参照材料を、超音波による解凝集後に、二倍濃縮粒子懸濁液として慎重に添加した。LDH放出及びCxcl2遺伝子発現の感受性の最適範囲を解明するために、それぞれの粒子を3つの異なった濃度(25、50及び75μg/cm2)で添加した。予備実験の後、異なる試料間の識別のための充分な応答を確実にすべく、前記範囲を75μm/cm2に設定した。
石英に関連するin vitro細胞モデルとしてはラット肺由来の一次肺胞マクロファージ(AM)を採用した。ラット由来の培養AMは石英及びクリストバライトの効果のスクリーニングのための非常に感度の高いin vitroモデル系であり、これは多くの例で示されていよう(例えば Ziemann et al., 2009; Ziemann et al., 2014; Ziemann et al., 2017)。
X線回折による結晶分画の決定
二酸化ケイ素の結晶分率の測定は、「SOP No. A04 R[oe]ntgendiffraktometrische Quarzfeinstaubbestim-mung gem[ae]B BGIA 8522 - Bestimmung von Cristobalit und Tridymit im A-Staub sowie Analyse kristalliner Kiesels[ae]uren in Materialproben; Dr. M. Kirchner, IGF Analytik Dr. H.-H. Fricke, IGF Analytik T. Faak; IGF Analytik; 04/2014」及び「ISO STANDARD 24095; First edition 2009-12-15; Workplace air-Guidance for the measurement of respirable crystalline silica」と同様に行われた。
LDH放出
ラットの一次肺胞マクロファージを試験材料及び参照材料と共にインキュベートした後、インキュベーション上清中のLDH活性を比色法によって測定した。
Cxcl2 RTqPCR(Δ-CT法)
異なる表面改変を有する石英粉試料の生物学的活性を評価するために、炎症誘発性「C-X-Cモチーフケモカインリガンド2」(Cxcl2)遺伝子の遺伝子発現をRT-qPCRにより測定することを、さらなるエンドポイントとして選択した。
LDH放出の場合の結果は、3連又は2連で順次測定された3つの培養物からの平均±関連標準偏差(SD)としてグラフで表される。
最初に、送達された12個の石英粉試料すべてについて、無菌性及びエンドトキシン含量を試験した。これは対応する汚染が石英粉にあるとin vitro試験において人工生物学的効果をもたらす可能性があるためである。
AMを75μ/cm2の試験物質及び標準物質と4時間インキュベートした後、エンドポイントであるLDH放出は非常に明瞭な画像をもたらした。陰性対照(細胞培養培地)及び粒子状陰性対照(Al2O3)は5.3±0.10%及び4.6±0.29%という低い細胞毒性値を有し、これは細胞の良好な活力を示したが、「活性」試料(DQ12 33797、38423及び38361)についてはすべて、粒子状陰性対照(P≦0.001;図2参照)に比べて、インキュベーション上清において有意に高いLDH活性が検出できた。陽性対照(DQ12)及び試料38361(DQ12 QW-陽性ブランク)は、細胞毒性が61.6±0.27%及び48.7±2.95%で、最も重篤な膜損傷を誘導した。試料38423(エアジェットミルでオートジェニックに(autogenically)粉砕されたばかりの石英)も、予想されたように、30.1±6.25%という高い細胞毒性を示した。主測定(図2)で16.0±0.42%の細胞毒性を有する基準石英粉37797(ボールミルで粉砕されたばかりの石英)は、活性濃度範囲を決定するための最初の測定(図1)(39.4±0.38%)よりも明らかに活性が低く、これはエイジング効果を示すものでありうる。しかしながら、残存する膜損傷効果の強度は、表面改変試料との明確な区別を可能にした。「活性」石英粉試料の膜損傷効果は、細胞をALで並行処理することにより、ほぼ完全に抑制することができた。
石英粉で処理した培養物のCxcl2遺伝子発現をさらなるエンドポイントとして測定した。
両方のin vitroエンドポイント(一次効果としてのLDH細胞毒性及び二次効果としてのCxcl2遺伝子発現)を考慮すれば、ポリグリコール(試料37935)又はグリセリン(試料38174)を用いた結晶性SiO2の処理は、同じ良好なクエンチ活性(quenching activity)を示した。従って、ラットの肺胞マクロファージに対するかかる改変結晶性SiO2粒子の負の効果は、もはやin vitroにおいて検出できなかった。すなわち、上述の表面改変は、陰性対照(培地及びAl2O3)と同じ大きさの効果を以って、粒状SiO2の細胞毒性的及び炎症誘発的能力の最高度の低減を仲介した。また、陰性の意味で活性であった(すなわち、生物学的に有害な効果を生じる)SiO2表面の部位の良好な「封鎖能力(sequestering potential)」が、アルミニウム化合物であるAlトリス-イソプロポキシド(試料38913)及びカオリンKBE-1(試料38272)によって示された。
Claims (15)
- 結晶性二酸化ケイ素を、多価アルコール、カオリン、アルミニウムアルコラート、及びそれらの混合物からなる群より選択される物質0.05重量%~1.00重量%と一緒に粉砕する工程を含む、結晶性二酸化ケイ素を処理するための方法。
- 前記結晶性二酸化ケイ素が、粉砕後に、0.2μm~90μmの範囲内、より好ましくは0.3μm~10μmの範囲内のd50粒径を有する、及び/又は粉砕後に、1μm~300μmの範囲内、好ましくは1μm~15μmの範囲内のd90粒径を有する、請求項1に記載の方法。
- 前記多価アルコールが、グリセリン、ポリエチレングリコール、ポリプロピレングリコール、並びにそれらの混合物及びコポリマーからなる群より選択される、請求項1又は請求項2に記載の方法。
- 前記多価アルコールのモル質量が90g/モル~50,000g/モルの範囲内である、請求項1~請求項3のいずれか一項に記載の方法。
- 前記結晶性二酸化ケイ素の結晶比率(crystalline proportion)が70%以上である、請求項1~請求項4のいずれか一項に記載の方法。
- 前記結晶性二酸化ケイ素が、石英、クリストバライト、又はトリジマイトである、請求項1~請求項5のいずれか一項に記載の方法。
- 前記処理が、結晶性二酸化ケイ素の細胞毒性的及び炎症誘発的能力を減少させる、請求項1~請求項6のいずれか一項に記載の方法。
- 結晶性二酸化ケイ素と、多価アルコール、アルミニウムアルコラート、カオリン、及びそれらの混合物からなる群より選択される物質0.05重量%~1.00重量%とを含む、結晶性二酸化ケイ素の製剤。
- 二酸化ケイ素を97重量%以上含む、請求項8に記載の結晶性二酸化ケイ素の製剤。
- 結晶比率が70%以上である二酸化ケイ素を含む、請求項8又は請求項9に記載の結晶性二酸化ケイ素の製剤。
- 前記結晶性二酸化ケイ素が、0.2μm~90μmの範囲内、より好ましくは0.3μm~10μmの範囲内のd50粒径を有する、請求項8、請求項9又は請求項10に記載の結晶性二酸化ケイ素の製剤。
- 結晶性二酸化ケイ素の細胞毒性的及び炎症誘発的能力を低下させるための多価アルコールの使用。
- 結晶性二酸化ケイ素の細胞毒性的及び炎症誘発的能力を減少させるためのカオリンの使用。
- 結晶性二酸化ケイ素の細胞毒性的及び炎症誘発的能力を減少させるためのアルミニウムアルコラートの使用。
- 請求項1~請求項7のいずれか一項に記載の方法によって得られる結晶性二酸化ケイ素の製剤。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19154567 | 2019-01-30 | ||
EP19154567.2 | 2019-01-30 | ||
EP19172386 | 2019-05-02 | ||
EP19172386.5 | 2019-05-02 | ||
PCT/EP2020/052286 WO2020157193A1 (de) | 2019-01-30 | 2020-01-30 | Maskierung von kristallinem siliciumdioxid |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022519249A true JP2022519249A (ja) | 2022-03-22 |
JP7453982B2 JP7453982B2 (ja) | 2024-03-21 |
Family
ID=69190812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021544602A Active JP7453982B2 (ja) | 2019-01-30 | 2020-01-30 | 結晶性二酸化ケイ素の封鎖 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220162080A1 (ja) |
EP (1) | EP3917881B9 (ja) |
JP (1) | JP7453982B2 (ja) |
KR (1) | KR20210118092A (ja) |
CN (1) | CN113423664A (ja) |
BR (1) | BR112021014856A2 (ja) |
CA (1) | CA3127921A1 (ja) |
ES (1) | ES2954908T3 (ja) |
PL (1) | PL3917881T3 (ja) |
TW (1) | TWI812835B (ja) |
WO (1) | WO2020157193A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5018003B1 (ja) * | 1969-02-26 | 1975-06-25 | ||
JP2005263566A (ja) * | 2004-03-19 | 2005-09-29 | Denki Kagaku Kogyo Kk | シリカフュームの圧密固化防止方法 |
JP2006307229A (ja) * | 2006-05-31 | 2006-11-09 | Nippon Paper Industries Co Ltd | 複合粒子の製造方法 |
WO2016031823A1 (ja) * | 2014-08-25 | 2016-03-03 | 新日鉄住金マテリアルズ株式会社 | 球状結晶性シリカ粒子およびその製造方法 |
US20180127322A1 (en) * | 2016-11-07 | 2018-05-10 | BeautyAvenues, LLC | Glaze Resistant to Wax Block Bonding, Ceramic Resistant to Wax Block Bonding and Preparation Process Thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5096733A (en) * | 1989-10-30 | 1992-03-17 | The United States Of America As Represented By The Secretary Of The Dept. Of Health And Human Services | Prevention of the acute cytotoxicity associated with silica containing minerals |
ATE424811T1 (de) * | 2000-08-31 | 2009-03-15 | Jagotec Ag | Gemahlene partikel |
ATE509891T1 (de) * | 2005-12-20 | 2011-06-15 | Evonik Degussa Gmbh | Pyrogen hergestelltes siliciumdioxid |
FI20070174A0 (fi) * | 2007-02-28 | 2007-02-28 | Delsitech Oy | Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt |
RU2011138097A (ru) * | 2009-03-18 | 2013-04-27 | Косентино, С.А. | Панель или плита, образованная из каменного агломерата, содержащего органическое связывающее растительного происхождения |
KR101345625B1 (ko) * | 2011-06-24 | 2013-12-31 | 서울대학교산학협력단 | 이산화규소 및 이산화규소를 함유한 광물을 이용한 리튬 이차전지용 음극활물질 및 그 제조방법 |
KR101443836B1 (ko) * | 2012-04-17 | 2014-09-30 | 송병옥 | 카올린(큐랙스)에서 알루미나와 실리카를 분리하는 장치 및 방법 |
CN103373844A (zh) * | 2012-04-24 | 2013-10-30 | 黄崧基 | 一种开采风化花岗岩矿山的资源综合利用的方法 |
JP6324396B2 (ja) * | 2012-11-12 | 2018-05-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 生物活性物質の改変放出のための酸化ケイ素ベース材料の使用 |
CN103274365B (zh) * | 2013-06-13 | 2015-02-25 | 南京大学 | 一种金属氧化物球形级联结构的制备方法 |
WO2016146079A1 (en) * | 2015-03-17 | 2016-09-22 | Sheau-Long Lee | Use of ginsenoside m1 for preventing or treating silicosis |
US11274045B2 (en) * | 2017-04-05 | 2022-03-15 | Nippon Steel Chemical & Material Co., Ltd. | Spherical crystalline silica particles and method for producing same |
CN109095907A (zh) * | 2018-09-28 | 2018-12-28 | 湖南华联瓷业股份有限公司 | 一种以石英为基体材料的高硅陶瓷和制备方法 |
-
2020
- 2020-01-21 TW TW109102126A patent/TWI812835B/zh active
- 2020-01-30 CN CN202080012056.2A patent/CN113423664A/zh active Pending
- 2020-01-30 WO PCT/EP2020/052286 patent/WO2020157193A1/de active Application Filing
- 2020-01-30 JP JP2021544602A patent/JP7453982B2/ja active Active
- 2020-01-30 US US17/426,461 patent/US20220162080A1/en active Pending
- 2020-01-30 KR KR1020217024076A patent/KR20210118092A/ko active Search and Examination
- 2020-01-30 ES ES20701793T patent/ES2954908T3/es active Active
- 2020-01-30 EP EP20701793.0A patent/EP3917881B9/de active Active
- 2020-01-30 BR BR112021014856A patent/BR112021014856A2/pt unknown
- 2020-01-30 PL PL20701793.0T patent/PL3917881T3/pl unknown
- 2020-01-30 CA CA3127921A patent/CA3127921A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5018003B1 (ja) * | 1969-02-26 | 1975-06-25 | ||
JP2005263566A (ja) * | 2004-03-19 | 2005-09-29 | Denki Kagaku Kogyo Kk | シリカフュームの圧密固化防止方法 |
JP2006307229A (ja) * | 2006-05-31 | 2006-11-09 | Nippon Paper Industries Co Ltd | 複合粒子の製造方法 |
WO2016031823A1 (ja) * | 2014-08-25 | 2016-03-03 | 新日鉄住金マテリアルズ株式会社 | 球状結晶性シリカ粒子およびその製造方法 |
US20180127322A1 (en) * | 2016-11-07 | 2018-05-10 | BeautyAvenues, LLC | Glaze Resistant to Wax Block Bonding, Ceramic Resistant to Wax Block Bonding and Preparation Process Thereof |
Non-Patent Citations (1)
Title |
---|
FUBINI B ET AL., SCAND J WORK ENVIRON HEALTH, vol. 21(2), JPN7023004038, 1995, pages 9 - 14, ISSN: 0005186497 * |
Also Published As
Publication number | Publication date |
---|---|
CA3127921A1 (en) | 2020-08-06 |
KR20210118092A (ko) | 2021-09-29 |
EP3917881A1 (de) | 2021-12-08 |
ES2954908T3 (es) | 2023-11-27 |
WO2020157193A1 (de) | 2020-08-06 |
EP3917881C0 (de) | 2023-06-07 |
US20220162080A1 (en) | 2022-05-26 |
BR112021014856A2 (pt) | 2021-12-21 |
TW202033450A (zh) | 2020-09-16 |
TWI812835B (zh) | 2023-08-21 |
PL3917881T3 (pl) | 2023-09-25 |
CN113423664A (zh) | 2021-09-21 |
EP3917881B9 (de) | 2023-09-27 |
JP7453982B2 (ja) | 2024-03-21 |
EP3917881B1 (de) | 2023-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Duffin et al. | Aluminium lactate treatment of DQ12 quartz inhibits its ability to cause inflammation, chemokine expression, and nuclear factor-κB activation | |
Gong et al. | The role of reactive oxygen species in silicon dioxide nanoparticle-induced cytotoxicity and DNA damage in HaCaT cells | |
Pirela et al. | Effects of laser printer–emitted engineered nanoparticles on cytotoxicity, chemokine expression, reactive oxygen species, DNA methylation, and DNA damage: a comprehensive in vitro analysis in human small airway epithelial cells, macrophages, and lymphoblasts | |
Singh et al. | Endocytosis, oxidative stress and IL-8 expression in human lung epithelial cells upon treatment with fine and ultrafine TiO2: role of the specific surface area and of surface methylation of the particles | |
Hasegawa et al. | Differential genotoxicity of chemical properties and particle size of rare metal and metal oxide nanoparticles | |
Scherbart et al. | Contrasting macrophage activation by fine and ultrafine titanium dioxide particles is associated with different uptake mechanisms | |
Morimoto et al. | Pulmonary toxicity of well-dispersed cerium oxide nanoparticles following intratracheal instillation and inhalation | |
Gminski et al. | Genotoxic effects of three selected black toner powders and their dimethyl sulfoxide extracts in cultured human epithelial A549 lung cells in vitro | |
Diefenbach et al. | The basic domain of herpes simplex virus 1 pUS9 recruits kinesin-1 to facilitate egress from neurons | |
Elias et al. | Cytotoxic and transforming effects of silica particles with different surface properties in Syrian hamster embryo (SHE) cells | |
EP3274452B1 (en) | Composition and method for disrupting tissue material | |
Zhang et al. | Studying the genotoxic effects induced by two kinds of bentonite particles on human B lymphoblast cells in vitro | |
Pezzotti et al. | Silicon nitride: a potent solid-state bioceramic inactivator of ssRNA viruses | |
Westphal et al. | Particle-induced cell migration assay (PICMA): a new in vitro assay for inflammatory particle effects based on permanent cell lines | |
Ziemann et al. | Organosilane-based coating of quartz species from the traditional ceramics industry: evidence of hazard reduction using in vitro and in vivo tests | |
Guo et al. | Progress in genotoxicity evaluation of engineered nanomaterials | |
Zeedan et al. | Evaluations of potential antiviral effects of green zinc oxide and silver nanoparticles against bovine herpesvirus-1 | |
Shim et al. | Differential MS2 interaction with food contact surfaces determined by atomic force microscopy and virus recovery | |
JP7453982B2 (ja) | 結晶性二酸化ケイ素の封鎖 | |
Hubbs et al. | Comparative pulmonary toxicity of 6 abrasive blasting agents | |
Hill et al. | Shielding of viruses such as SARS-Cov-2 from ultraviolet radiation in particles generated by sneezing or coughing: Numerical simulations of survival fractions | |
RU2810166C2 (ru) | Маскировка кристаллического диоксида кремния | |
Pan et al. | Sprayable copper and copper–zinc nanowires inks for antiviral surface coating | |
Wohlleben et al. | Artifacts by marker enzyme adsorption on nanomaterials in cytotoxicity assays with tissue cultures | |
Porter et al. | Comparative pulmonary toxicity of blasting sand and five substitute abrasive blasting agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221101 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231025 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240130 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240227 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240308 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7453982 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |